- Home
- BXMX vs ARDX Comparison
BXMX vs ARDX Comparison
Compare BXMX & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXMX
- ARDX
- Stock Information
- Founded
- BXMX 2004
- ARDX 2007
- Country
- BXMX United States
- ARDX United States
- Employees
- BXMX N/A
- ARDX N/A
- Industry
- BXMX Investment Managers
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- BXMX Finance
- ARDX Health Care
- Exchange
- BXMX Nasdaq
- ARDX Nasdaq
- Market Cap
- BXMX 1.5B
- ARDX 1.3B
- IPO Year
- BXMX N/A
- ARDX 2014
- Fundamental
- Price
- BXMX $13.03
- ARDX $4.93
- Analyst Decision
- BXMX
- ARDX Strong Buy
- Analyst Count
- BXMX 0
- ARDX 9
- Target Price
- BXMX N/A
- ARDX $10.61
- AVG Volume (30 Days)
- BXMX 205.6K
- ARDX 3.9M
- Earning Date
- BXMX 01-01-0001
- ARDX 05-01-2025
- Dividend Yield
- BXMX 7.24%
- ARDX N/A
- EPS Growth
- BXMX N/A
- ARDX N/A
- EPS
- BXMX N/A
- ARDX N/A
- Revenue
- BXMX N/A
- ARDX $333,615,000.00
- Revenue This Year
- BXMX N/A
- ARDX $14.26
- Revenue Next Year
- BXMX N/A
- ARDX $32.49
- P/E Ratio
- BXMX N/A
- ARDX N/A
- Revenue Growth
- BXMX N/A
- ARDX 168.06
- 52 Week Low
- BXMX $11.75
- ARDX $4.32
- 52 Week High
- BXMX $13.75
- ARDX $9.33
- Technical
- Relative Strength Index (RSI)
- BXMX 36.51
- ARDX 40.37
- Support Level
- BXMX $12.90
- ARDX $5.00
- Resistance Level
- BXMX $13.39
- ARDX $5.56
- Average True Range (ATR)
- BXMX 0.16
- ARDX 0.27
- MACD
- BXMX 0.03
- ARDX -0.04
- Stochastic Oscillator
- BXMX 37.93
- ARDX 2.44
About BXMX Nuveen S&P 500 Buy-Write Income Fund of Beneficial Interest
Nuveen S&P 500 Buy-Write Income Fund is a diversified closed-ended management investment company based in the United States. Its investment objective is to seek attractive total returns with less volatility. The fund invests its managed assets in a diversified equity portfolio that seeks to substantially replicate price movements of the S&P 500 Index. It also uses an index options strategy of writing (selling) index call options in seeking to moderate the volatility of returns relative to an all-equity portfolio. Its revenue is generated mainly from interest and dividend income.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.